Edition:
United Kingdom

BioCryst Pharmaceuticals Inc (BCRX.OQ)

BCRX.OQ on NASDAQ Stock Exchange Global Select Market

5.94USD
20 Jul 2018
Change (% chg)

$-0.12 (-1.98%)
Prev Close
$6.06
Open
$6.05
Day's High
$6.11
Day's Low
$5.94
Volume
111,634
Avg. Vol
207,693
52-wk High
$6.69
52-wk Low
$3.95

Latest Key Developments (Source: Significant Developments)

Biocryst Pharmaceuticals Entered $30 Million Secured Loan Facility
Friday, 20 Jul 2018 

July 20 (Reuters) - BioCryst Pharmaceuticals Inc ::BIOCRYST PHARMACEUTICALS INC - CO, UNITS, ENTERED A $30 MILLION SECURED LOAN FACILITY - SEC FILING.BIOCRYST PHARMACEUTICALS - USING PROCEEDS OF NEW LOAN TO PAY OFF OUTSTANDING AMOUNTS UNDER PRIOR CREDIT AGREEMENT.  Full Article

Biocryst Provides Update On Strategy, Pipeline And Outlook
Wednesday, 11 Jul 2018 

July 11 (Reuters) - BioCryst Pharmaceuticals Inc ::BIOCRYST PROVIDES UPDATE ON STRATEGY, PIPELINE AND OUTLOOK.BIOCRYST PHARMACEUTICALS INC - CONTINUE TO EXPECT TO REPORT TOP-LINE RESULTS FROM 750 MG COHORT IN Q3 OF 2018.BIOCRYST PHARMACEUTICALS INC - EXECUTING A STRATEGIC PLAN.BIOCRYST - ON TRACK FOR H1 2019 INITIATION OF PHASE 1 CLINICAL TRIAL FOR ALK-2 INHIBITOR PROGRAM FOR TREATING FIBRODYSPLASIA OSSIFICANS PROGRESSIVA.BIOCRYST PHARMACEUTICALS INC - HAS REVISED ITS STAND-ALONE 2018 GUIDANCE AND EXPECTS ITS 2018 NET OPERATING CASH USE TO BE IN RANGE OF $85 TO $105 MILLION.BIOCRYST PHARMACEUTICALS INC - 2018 OPERATING EXPENSES TO BE IN RANGE OF $90 TO $110 MILLION.BIOCRYST PHARMACEUTICALS INC - EXPECT TO REPORT TOP-LINE RESULTS FROM ZENITH-1 750 MG COHORT IN Q3 2018.BIOCRYST PHARMACEUTICALS INC - EXPECTS 2018 NET OPERATING CASH USE TO BE IN RANGE OF $85 TO $105 MILLION.  Full Article

Biocryst Pharmaceuticals Says Merger Agreement Terminated With Idera Pharmaceuticals
Tuesday, 10 Jul 2018 

July 11 (Reuters) - BioCryst Pharmaceuticals Inc ::BIOCRYST PHARMACEUTICALS ANNOUNCES TERMINATION OF MERGER AGREEMENT WITH IDERA PHARMACEUTICALS.BIOCRYST PHARMACEUTICALS INC - TERMINATED PREVIOUSLY ANNOUNCED MERGER AGREEMENT WITH IDERA PHARMACEUTICALS.BIOCRYST PHARMACEUTICALS INC - IN ACCORDANCE WITH TERMS OF MERGER AGREEMENT, BIOCRYST WILL REIMBURSE IDERA FOR TRANSACTION-RELATED EXPENSES OF $6 MILLION.BIOCRYST - TERMINATED MERGER AGREEMENT AFTER BIOCRYST STOCKHOLDERS' FAILURE TO APPROVE ADOPTION OF MERGER AGREEMENT AT SPECIAL MEETING.  Full Article

Great Point Partners Says Delivered Letter To Biocryst Pharma
Wednesday, 20 Jun 2018 

June 20 (Reuters) - BioCryst Pharmaceuticals Inc ::GREAT POINT PARTNERS SAYS DELIVERED LETTER TO BIOCRYST PHARMACEUTICALS REAFFIRMING ITS OBJECTIONS TO PROPOSED MERGER OF BIOCRYST & IDERA PHARMACEUTICALS.  Full Article

Biocryst Urges Stockholders To Vote "For" Merger Transaction With Idera
Tuesday, 5 Jun 2018 

June 5 (Reuters) - BioCryst Pharmaceuticals Inc ::BIOCRYST PHARMACEUTICALS INC SAYS URGE STOCKHOLDERS TO VOTE "FOR" MERGER TRANSACTION WITH IDERA PHARMACEUTICALS.  Full Article

Biocryst Pharmaceuticals Q1 Loss Per Share $0.26
Tuesday, 8 May 2018 

May 8 (Reuters) - BioCryst Pharmaceuticals Inc ::BIOCRYST REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.26.Q1 REVENUE $4.0 MILLION VERSUS $9.4 MILLION.Q1 REVENUE VIEW $6 MILLION -- THOMSON REUTERS I/B/E/S.Q1 EARNINGS PER SHARE VIEW $-0.19 -- THOMSON REUTERS I/B/E/S.BIOCRYST CONTINUES TO EXPECT ITS 2018 NET OPERATING CASH USE TO BE IN RANGE OF $67 TO $90 MILLION.  Full Article

BioCryst Receives European Medicines Agency Approval For Alpivab For Treatment Of Influenza
Tuesday, 1 May 2018 

May 1 (Reuters) - BioCryst Pharmaceuticals Inc ::BIOCRYST RECEIVES EUROPEAN MEDICINES AGENCY APPROVAL FOR ALPIVAB™ FOR TREATMENT OF INFLUENZA.  Full Article

Biocryst Pharma And Idera Pharma Sign Merger Agreement To Form New Company
Monday, 22 Jan 2018 

Jan 22 (Reuters) - Biocryst Pharmaceuticals Inc ::BIOCRYST PHARMACEUTICALS AND IDERA PHARMACEUTICALS ANNOUNCE MERGER TO COMBINE CAPABILITIES TO SERVE MORE PATIENTS WITH RARE DISEASES.IDERA PHARMACEUTICALS INC - ‍MERGER AGREEMENT HAS BEEN UNANIMOUSLY APPROVED BY BOARDS OF DIRECTORS OF BOTH COMPANIES​.IDERA PHARMACEUTICALS INC - ROBERT INGRAM TO BE CHAIRMAN OF BOARD, VINCENT MILANO TO BE CEO OF COMBINED COMPANY.IDERA PHARMACEUTICALS - UNDER TERMS OF MERGER AGREEMENT, EACH SHARE OF BIOCRYST COMMON STOCK WILL BE EXCHANGED FOR 0.50 SHARES OF NEW COMPANY STOCK.IDERA PHARMACEUTICALS - UNDER TERMS OF MERGER AGREEMENT, EACH SHARE OF IDERA COMMON STOCK WILL BE EXCHANGED FOR 0.20 SHARES OF NEW COMPANY STOCK.IDERA PHARMACEUTICALS - ‍SIGNIFICANT STOCKHOLDER OF CO, BIOCRYST AGREED TO ENTER VOTING AND SUPPORT AGREEMENT AND HAS AGREED TO VOTE IN FAVOR OF DEAL​.IDERA PHARMACEUTICALS INC - AFTER DEAL BIOCRYST STOCKHOLDERS WILL OWN 51.6 PERCENT OF STOCK OF COMBINED COMPANY, CO'S STOCKHOLDERS TO OWN 48.4 PERCENT.IDERA PHARMACEUTICALS - COMBINED COMPANY, WHICH WILL BE RENAMED POST-CLOSING, WILL BE HEADQUARTERED AT CURRENT IDERA HEADQUARTERS.IDERA PHARMACEUTICALS INC - STOCK ISSUANCE IN MERGER IS EXPECTED TO BE TAX-FREE TO STOCKHOLDERS.  Full Article

BioCryst Pharma files for mixed shelf of up to $200 million‍​
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - BioCryst Pharmaceuticals Inc :Files for mixed shelf of up to $200 million - SEC filing‍​.  Full Article

BioCryst Pharmaceuticals reports Q3 loss per share of $0.18
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - BioCryst Pharmaceuticals Inc ::Reports third quarter 2017 financial results.Q3 loss per share $0.18.Q3 revenue $8.8 million versus $7.8 million.Q3 earnings per share view $-0.19 -- Thomson Reuters I/B/E/S.Q3 revenue view $4.6 million -- Thomson Reuters I/B/E/S.Expect to start single required phase 3 efficacy and long-term safety trials for BCX7353 in Q1 2018 ​.‍U.S. Orphan Drug Designation for BCX7353 received from FDA​.  Full Article